Aspire Biopharma Holdings, Inc.
ASBP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.02 | 0.01 | 0.01 |
| FCF Yield | -10.82% | -8.59% | -7.93% | 2.70% |
| EV / EBITDA | 4.77 | 0.00 | 0.00 | -7.60 |
| Quality | ||||
| ROIC | 11.37% | 0.00% | 0.00% | -1,316.49% |
| Gross Margin | 45.54% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.60 | 0.58 | 0.11 | 1.12 |
| Growth | ||||
| Revenue 3-Year CAGR | 124,640.80% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 3.20% | 34.90% | -168.38% | 9,943.99% |
| Safety | ||||
| Net Debt / EBITDA | -0.28 | 0.00 | 0.00 | -0.10 |
| Interest Coverage | -0.77 | 0.00 | 0.00 | -3.35 |
| Efficiency | ||||
| Inventory Turnover | 0.03 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -87,313.79 | 0.00 | 0.00 | 0.00 |